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Abstract: Aims For patients undergoing cardiac resynchronization therapy (CRT) with implantable
cardioverter-defibrillator (ICD; CRT-D), the effect of an improvement in left ventricular ejection fraction
(LVEF) on appropriate ICD therapy may have significant implications regarding management at the
time of ICD generator replacement. Methods and results We conducted a meta-analysis to determine the
effect of LVEF recovery following CRT on the incidence of appropriate ICD therapy. A search of multiple
electronic databases identified 709 reports, of which 6 retrospective cohort studies were included (n =
1740). In patients with post-CRT LVEF ￿35% (study n = 4), the pooled estimated rate of ICD therapy
(5.5/100 person-years) was significantly lower than patients with post-CRT LVEF <35% [incidence rate
difference (IRD): −6.5/100 person-years, 95% confidence interval (95% CI): −8.8 to −4.2, P < 0.001].
Similarly, patients with post-CRT LVEF ￿45% (study n = 4) demonstrated lower estimated rates of ICD
therapy (2.3/100 person-years) compared with patients without such recovery (IRD: −5.8/100 person-
years, 95% CI: −7.6 to −4.0, P < 0.001). Restricting analysis to studies discounting ICD therapies during
LVEF recovery (study n = 3), patients with LVEF recovery (￿35 or ￿45%) had significantly lower rates of
ICD therapy compared with patients without such recovery (P for both <0.001). Patients with primary
prevention indication for ICD, regardless of LVEF recovery definition, had very low rates of ICD therapy
(0.4 to 0.8/100-person years). Conclusion Recovery of LVEF post-CRT is associated with significantly
reduced appropriate ICD therapy. Patients with improvement of LVEF ￿45% and those with primary
prevention indication for ICD appear to be at lowest risk
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Aims For patients undergoing cardiac resynchronization therapy (CRT) with implantable cardioverter-defibrillator (ICD;
CRT-D), the effect of an improvement in left ventricular ejection fraction (LVEF) on appropriate ICD therapy may
have significant implications regarding management at the time of ICD generator replacement.
Methods
and results
We conducted a meta-analysis to determine the effect of LVEF recovery following CRT on the incidence of appropriate
ICD therapy. A search of multiple electronic databases identified 709 reports, of which 6 retrospective cohort studies
were included (n ¼ 1740). In patients with post-CRT LVEF ≥35% (study n ¼ 4), the pooled estimated rate of ICD ther-
apy (5.5/100 person-years) was significantly lower than patients with post-CRT LVEF ,35% [incidence rate difference
(IRD): 26.5/100 person-years, 95% confidence interval (95% CI): 28.8 to 24.2, P, 0.001]. Similarly, patients with
post-CRT LVEF ≥45% (study n ¼ 4) demonstrated lower estimated rates of ICD therapy (2.3/100 person-years) com-
paredwith patients without such recovery (IRD:25.8/100 person-years, 95%CI:27.6 to24.0, P, 0.001). Restricting
analysis to studies discounting ICD therapies during LVEF recovery (study n ¼ 3), patients with LVEF recovery (≥35 or
≥45%) had significantly lower rates of ICD therapy comparedwith patients without such recovery (P for both,0.001).
Patients with primary prevention indication for ICD, regardless of LVEF recovery definition, had very low rates of ICD
therapy (0.4 to 0.8/100-person years).
Conclusion Recovery of LVEF post-CRT is associated with significantly reduced appropriate ICD therapy. Patients with improve-
ment of LVEF ≥45% and those with primary prevention indication for ICD appear to be at lowest risk.
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Introduction
Cardiac resynchronization therapy (CRT) has become a standard
therapy in appropriately selected patients with left ventricular systolic
dysfunction (LVSD), symptomatic heart failure, and electrical dyssyn-
chrony. Resynchronization of the failing heart leads to favourable ven-
tricular reverse remodelling characterized by reduced LV volumes and
improved LV ejection fraction (LVEF), ultimately translating to signifi-
cant reductions in morbidity and mortality.1 In conjunction with CRT,
many patients undergo implantation of an implantable cardioverter-
defibrillator (ICD; CRT-D) given its efficacy in the prevention of sud-
den cardiac death (SCD) in patients with systolic heart failure.2
Given the salutary effects of CRT on LV function, and the estab-
lished relationship between risk of ventricular tachyarrhythmia
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(VTA) and LVEF, there has been significant interest regarding the
impact of CRT-induced improvement in LV function and risk
of VTA.3 – 9 To the extent that contemporary ICD implantation
guidelines rely on LVEF assessment,10 the impact of CRT and
LVEF improvement on VTA risk has substantial clinical and cost-
effectiveness implications at the time of ICD generator replacement.
In addition, identification of patients likely to experience CRT-
related improvement in LVEF and possibly attenuated future
risk of VTA may further impact the selection of CRT-pacing
(CRT-P) vs. CRT-D.
To date, there are no prospective, randomized studies assessing
the efficacy of ICD implantation in patients with post-CRT LVEF re-
covery. Given the clinical equipoise and the expanding population of
patients for whom this decision-making will be impactful, we con-
ducted a meta-analysis of cohort studies assessing the incidence
of VTA in patients with LVEF recovery following CRT. We report
subset analyses stratified by the degree of LVEF improvement, the
timing of VTA assessment in relation to LVEF recovery, and the in-
dex indication for ICD implantation.
Methods
Search strategy
We performed an electronic literature search of MEDLINE (1948
to December 2014), MEDLINE In-Process and Other Non-Indexed
Citations, Cumulative Index to Nursing and Allied Health Literature,
the Cochrane Database of Systematic Reviews (Fourth Quarter,
2010), the American College of Physicians Journal Club (1991 to
November 2011), Database of Abstracts of Reviews of Effects, and
the Cochrane Central Register of Controlled Trials using the following
search terms: biventricular, resynchronization, arrhythmia, recovery,
improvement, ICD, defibrillator, and responder (see Supplementary
material online, Appendix S1). We also hand searched the bibliographies
of all review articles published in the past 5 years discussing ICD therapy
and CRT.
We included published data from retrospective cohort studies as-
sessing ICD therapy in patients with and without LVEF improvement
following CRT. We selected studies which defined comparator
groups using discrete LVEF cutpoints (e.g. ≥35%) and assessed the in-
cidence of appropriate ICD therapies [defined as patients with appro-
priate shock or anti-tachycardia pacing (ATP)]. In a subgroup analysis,
we analysed studies in which ICD therapies were assessed after
follow-up LVEF assessment (i.e. ICD therapies occurring between
CRT implant and follow-up LVEF assessment were not counted in
the primary endpoint). Reports in which comparator groups were
not defined by discrete LVEF cutpoints (CRT responder vs. non-
responder) were excluded, as were studies including patients with
both CRT-D and CRT-P.
Data extraction
Two investigators (N.A.C. and A.R.) independently extracted data on
patient and study characteristics, outcomes, and study quality for each
trial. The Meta-analysis of Observational Studies in Epidemiology
checklist for observational studies was utilized for study selection and
review.11 Study quality was assessed qualitatively using the Downs and
Black checklist.12 Disagreements were resolved by consensus (N.A.C
and A.R.).
Data analysis
The estimated incidence rates for groups of interest were calculated
using the number of patients with appropriate ICD therapies and the
person-years of follow-up derived from subgroupN and median follow-
up, as previously described.13 Estimated incidence rates are reported as
per 100 person-years. Median follow-up time was defined as the time of
assessment of ICD therapies which began (i) immediately following CRT
implant in three studies3,8,9 and (ii) after follow-up LVEF assessment in
three studies (i.e. studies blanked ICD therapies prior to follow-up LVEF
assessment).4–6 The IRD between groups was calculated using the in-
verse variance fixed-effects model in StatsDirect (StatsDirect Ltd, Lon-
don, England). A fixed-effect model was selected to minimize instability
related to estimating random, study-level effects given the limited num-
ber of studies. A sensitivity analysis was performed using a DerSimonian-
Laird random-effects model (StatsDirect Ltd) with no change to the
study results. Heterogeneity was quantified using the I2 statistic (a value
of 0% indicates minimal heterogeneity).14 Bias was assessed using the Eg-
ger’s regression test.15 Pre-specified subgroup analysis was performed
for studies which discounted ICD therapies occurring prior to
post-CRT LVEF reassessment.
Results
Search results
The initial search yielded 709 reports, of which 6 3–6,8,9 met inclu-
sion criteria (Figure 1). Five of the six studies selected were retro-
spective, cohort studies3,4,6,8,9 whereas one was a post hoc analysis
of a randomized controlled trial (Multicenter Automatic Defibrilla-
tor Implantation Trial, MADIT-CRT).5 The method of ICD therapy
adjudication was described in all but one study,8 although assess-
ment was blinded in only one study (Supplementary material online,
Table S1).5 Four studies described a frequency protocol for end-
point assessment.3,5,6,9 While all studies clearly define and report
the endpoint of interest (appropriate ICD therapies), only two stud-
ies additionally reported incident inappropriate therapies.5,9
Selected studies included a total of 1740 patients with relatively
advanced LVSD (average or median LVEF range: 20–29%; Table 1).
Of studies reporting New York Heart Association (NYHA)
class,3,4,6,9 there was a range of heart failure (HF) symptom severity
(45–86% NYHA III). The prevalence of AF varied across studies
(10–40%) as did use of anti-arrhythmic medications (8–29%).
Of studies reporting the index indication for ICD implantation a sig-
nificant majority of patients (≥75% of each study population)
underwent implant for primary prevention. The timing of echocar-
diographic assessment for delineation of LVEF recovery was hetero-
geneous and ranged from 4 to 20 months post-implant. With
respect to stratification of LVEF recovery, two studies assessed mo-
dest recovery of LV function (LVEF ≥35%),6,9 two studies assessed
the impact of significant LVEF recovery (LVEF ≥45–50%),3,4 and
two studies stratified at both levels of LVEF (modest and significant
recovery).5,8 All studies utilized the presence of ATP or defibrillator
therapy, as reviewed by electrophysiologists, to define appropriate
ICD therapy although programming details were only available in a
minority of studies,5,6 and not standardized. The median follow-up
range for VTA assessment was 1.5–3 years (3719 estimated person-
years of follow-up). Finally, three studies4–6 assessed ICD therapies
after post-CRT LVEF assessment (i.e. ICD therapies between CRT
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implant and echocardiographic follow-up were blanked), whereas
the remainder assessed ICD therapies from the time of CRT
implant.
Implantable cardioverter-defibrillator
therapies associated with left ventricular
ejection fraction recovery ≥35% after
cardiac resynchronization therapy
Of studies reporting appropriate ICD therapies in patients with mo-
dest LVEF recovery (≥ vs. ,35%; study n ¼ 4),5,6,8,9 the estimated
pooled incidence rate of appropriate therapy in patients with
post-CRT LVEF ≥35% was 5.4/100 person-years and significantly
lower than in patients without such recovery [(IRD): 26.1/100
person-years, 95% confidence interval (CI): 28.2 to 24.0,
P, 0.001] (Figures 2A and 3). There was no identified heterogeneity
across studies (I2 ¼ 0%) and no evidence of systematic bias (Egger
P ¼ 0.74). In subgroup analysis of studies in which ICD therapies
prior to follow-up LVEF assessment were blanked (study n ¼
2),5,6 the absolute pooled rate of appropriate ICD therapy was
5.6/100 person-years in patients with LVEF ≥35% and significantly
lower than patients with post-CRT LVEF ,35% (IRD: 27.5/100
person-years, 95% CI: 211.4 to 23.6, P, 0.001; Figures 2B
and 3). Only one study reported the relative timing of ICD therapy
in each LVEF strata.6 Of patients with LVEF recovery to ≥35%
(n ¼ 57), 38% of appropriate ICD therapies occurred in the first
12 months following CRT implant (5 of 13). This proportion was
generally similar to patients without LVEF recovery (,35%;
n ¼ 212), for whom 31% of appropriate ICD therapies occurred
in the first year after CRT (25 of 81).
Implantable cardioverter-defibrillator
therapies associated with left ventricular
ejection fraction ≥45% after cardiac
resynchronization therapy
Of studies which assessed ICD therapies in patients with vs. without
significant LVEF improvement (LVEF ≥45–50%),3–5,8 the absolute
pooled rate of appropriate ICD therapies in patients with LVEF
≥45% was 2.3/100 person-years and significantly lower than in pa-
tients without LVEF such improvement (IRD:25.9, 95%CI:27.6 to
24.1, P, 0.001; Figures 3 and 4B). There was minimal heterogen-
eity or bias (I2 ¼ 0%, Egger P ¼ 0.39). Of studies which blanked
ICD therapies prior to LVEF assessment (study n ¼ 2),4,5 the abso-
lute pooled rate of ICD therapy in patients with significant LVEF re-
covery was very low (1.7/100 person-years) and significantly lower
than in patients without such recovery (IRD: 25.5, 95% CI: 27.5 to
23.5, P, 0.001; Figures 3 and 4B).
Figure 1 Search strategy.
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Table 1 Baseline characteristics and endpoint adjudication of included studies
Schaer 2010 Manfredi
2013
Ruwald 2015 Steffel 2011 Van Boven
2013
Garcia-Lunar
2014
N 270 270a 752 110 142 196
Age, years 60.9 (11.1) 71 [64–77] 65 (2) 63.1 (10.9) 69 [61–74] 63 (2)
Women, (%) 23 28 25 18 30 15
LVEF baseline, % 22 (5) 20 [15–25] 29 (1) 26 (8) 20 [18–25] 26 (1)
ICD indication, (%)
Primary 75 100 93 100 81
Secondary 25 0 7 — 0 19
Ischaemic
cardiomyopathy, %
48 59 55 44 53 46
NYHA class, %
II 27 2 52 21
III 68 86 — 45 76
IV 5 12 — 3 3
Atrial fibrillation, % 21 40 10 14 26 —
QRSd, ms 165 (28) 154 [133–174] 159 (4) 154 (29) 71% with QRS
.150
161 (5)
Medications
b-blocker 77 97 94 91 87
Digoxin 28 — 27 — —
ACEi/ARB 94 84 95 98 85
AADs 29 18 8 — — 37
Time of LVEF assessment
post-CRT implant,
months
20 (15) 7 [7–13] 12 6.4 (2.7) 4 12
LVEF recovery definition ≥ vs. ,35% ≥ vs. ,45% .50%, 36–50%,
≤35%
≥ vs. ,35%,
≥ vs. ,45%
≥ vs. ,35% ≥ vs. ,45%
% with LVEF recovery 21 14 86 (.35%)
7 (.50%)
46 (.35%)
17 (.45%)
30 26
Definition of ICD therapy ATP or shock in VT/
VF zone
ATP or shock in
VT/VF zone
ATP or shock in VT/
VF zone
ATP or shock
in VT/VF
zone
ATP or shock
in VT/VF
zone
ATP or shock in
VT/VF zone
VT Zone
18 prevention
175–180 b.p.m.
with initial ATP
28 prevention
155–160 b.p.m.
with initial ATP
VT Zone
180–250 b.p.m.
with initial ATP
Programming details VF Zone
DCCV at
≥210 b.p.m.
Provider
Discretion
VF Zone
DCCV at
≥250 b.p.m.
Provider
Discretion
Provider
Discretion
Provider
Discretion
Median follow-up, yearsb 1.9 1.5 2.2 2.1 3 2.5
Blankingc of ICD therapies
prior to LVEF
reassessment
Yes Yes Yes No No No
Data are presented as either average (standard deviation) or median [interquartile range] as appropriate.
LVEF, left ventricular ejection fraction; ICD, implantable cardioverter-defibrillator; NYHA, New York Heart Association class; QRSd, QRS duration; ACEi/ARB, angiotensin
converting enzyme inhibitor/angiotensin receptor blocker; AADs, anti-arrhythmic drugs (Vaughn-Williams Class III); CRT, cardiac resynchronization therapy; ATP, anti-tachycardia
pacing; VT/VF, ventricular tachycardia/ventricular fibrillation; b.p.m., beats per minutes; DCCV, direct current cardioversion.
aBaseline characteristics are provided for subgroup of population (N ¼ 289), whereas the landmark population of interest utilized in meta-analysis was smaller (N ¼ 270).
bMedian follow-up is for time after follow-up LVEF assessment in studies which blank for ICD therapies prior to LVEF assessment. For studies without blanking, follow-up time is
defined after CRT implant.
cBlanking refers to studies which did not count ICD therapies occurring between CRT implant and time of LVEF reassessment.
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Figure 2 Incidence rate difference of appropriate implantable cardioverter defibrillator therapy in patients with post-cardiac resynchronization
therapy left ventricular ejection fraction recovery to ≥35%. Incidence rate difference (IRD) of patients with appropriate implantable cardioverter
defibrillator therapy and post-cardiac resynchronization therapy left ventricular ejection fraction ≥35% compared with patients with post-cardiac
resynchronization therapy left ventricular ejection fraction ,35% for all studies (A) and for studies which blanked implantable cardioverter de-
fibrillator therapies occurring between cardiac resynchronization therapy implant and follow-up left ventricular ejection fraction assessment (B).
Shown are pooled incidence rate differences. CI, confidence interval.
Figure 3 Summary of appropriate implantable cardioverter defibrillator (ICD) therapy stratified by left ventricular ejection fraction improve-
ment and presence of post-implant blanking. Shown are the absolute pooled rates of appropriate implantable cardioverter defibrillator therapy for
patients with post-implantable cardioverter defibrillator left ventricular ejection fraction (LVEF) recovery (blue diamond; ≥35 or 45% where in-
dicated) as well as the pooled estimated incidence rate difference (with 95% confidence interval) in patients without such recovery. Groups are
stratified by the presence or absence of blanking implantable cardioverter defibrillator therapies occurring between cardiac resynchronization
therapy implant and follow-up left ventricular ejection fraction assessment. Dashed line indicates the estimated annual arrhythmic mortality
(3%) associated with a number needed to treat (NNT) effectiveness estimate of 50 for implantable cardioverter-defibrillator implant (see text).
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Implantable cardioverter-defibrillator
therapies stratified by index implantable
cardioverter-defibrillator indication
Of studies stratifying patients by post-CRT LVEF ≥ vs. ,35%, one
provided detailed information regarding ICD therapies in patients
with a primary prevention indication (ICD therapies blanked in first
year after CRT)6 and another exclusively enrolled patients with a
primary prevention indication (ICD therapies counted immediately
post-CRT).9 The pooled absolute rate of appropriate ICD therapy
in patients with post-CRT LVEF ≥35%was very low (0.4/100 person-
years) compared with patients without such recovery (9.0/100
person-years). Only one study stratifying patients by post-CRT
LVEF recovery to ≥45% vs. ,45% reported ICD rates for patients
with primary prevention ICD which were numerically lower in pa-
tients with LVEF recovery (0.8 vs. 5.5/100 person-years).4
Discussion
This meta-analysis represents the first systematic synthesis of avail-
able cohort studies assessing the incidence of VTA in patients
undergoing CRT with LVEF recovery. The central findings of this
study are: (i) the presence of LVEF recovery following CRT is asso-
ciated with significant reduction in the risk of VTA compared with
patients without such recovery. (ii) The reduction of VTA with
LVEF recovery was present regardless of the context of ICD therapy
assessment (post-implant vs. post-LVEF reassessment). (iii) Patients
with recovery of LVEF ≥45% and those with LVEF recovery in the
context of a primary prevention ICD indication were at particularly
low risk.
The incremental efficacy of ICD therapy over CRT-P alone has
never been directly established as highlighted by previous
meta-analysis16 and consensus guidelines.10 In the only randomized
controlled trial to include both CRT-P and CRT-D arms (Compari-
son of Medical Therapy, Pacing, and Defibrillation in Heart Failure,
COMPANION), both CRT modes were associated with significant
reduction in the composite endpoint of death or HF hospitalization
in an advanced HF population (86% NYHA class III).17 Over a rela-
tively short duration of follow-up (mean 14 months), CRT-D ther-
apy demonstrated a statistically significant 36% relative reduction in
mortality compared with optimal medical therapy (OMT), whereas
CRT-P was associated with a numeric trend to reduced mortality
(24% risk reduction, P ¼ 0.06). In post hoc analysis, CRT-D (but
not CRT-P) was associated with a significant reduction in SCD com-
paredwithOMT.18 In contrast to the null findings of COMPANION,
longer-term follow-up of the CARE-HF study (mean follow-up: 37
months) identified a significant, delayed reduction in SCD with
CRT-P alone ( vs. OMT) in patients with similarly advanced HF
(46% risk reduction, P ¼ 0.006).19
The combination of these findings—the early reduction in SCD
with CRT-D alone and the delayed SCD reduction of CRT-P vs.
OMT—has led several to suggest an anti-arrhythmic benefit asso-
ciated with the salutary effects of CRT on LV function, NYHA class,
and autonomic function.20 – 22 Indeed, several studies have
Figure 4 Incidence rate difference of appropriate implantable cardioverter defibrillator therapy in patients with post-cardiac resynchronization
therapy left ventricular ejection fraction recovery to ≥45%. Incidence rate difference of patients with appropriate implantable cardioverter de-
fibrillator therapy and post-cardiac resynchronization therapy left ventricular ejection fraction ≥45% compared with patients with post-cardiac
resynchronization therapy left ventricular ejection fraction ,45% for all studies (A) and for studies which blanked implantable cardioverter de-
fibrillator therapies occurring between cardiac resynchronization therapy implant and follow-up left ventricular ejection fraction assessment (B).
Shown are pooled incidence rate differences. CI, confidence interval; IRD, incidence rate difference.
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demonstrated an association between CRT response (defined by
improvement in LVEF, reduction in LV volume, and/or NYHA class)
and a reduced risk of VTA compared with CRT non-
responders.21,22 In some studies, the reduction in VTAwas apparent
within 1 month of implant.21 In addition to VTA reduction, others
have suggested that normalization of LVEF following CRT is asso-
ciated with normalization of survival compared with age- and
gender-matched controls.23
Left ventricular ejection fraction recovery
after cardiac resynchronization therapy:
impact on appropriate implantable
cardioverter-defibrillator therapies
While response to CRT has been variably defined,24 given the focus
of contemporary ICD implant guidelines on absolute LVEF,10 we re-
stricted our analysis to studies comparing VTA in groups defined by
discrete post-CRT LVEF cutpoints. In the studies included here
(baseline average LVEF 20–29%), nearly two-thirds of patients de-
monstrated post-CRT LVEF ≥35% (63%) and 10% had LVEF recov-
ery to ≥45% after implant. And while the incidence of LVEF
recovery is related to the prevalence of baseline predictors of LV re-
verse remodelling [e.g. female gender, non-ischaemic aetiology, left
bundle branch abnormality (LBBB), QRS ≥ 150 ms], the rates re-
ported in this analysis are similar to previous reports of significant
LVEF recovery to ≥45% (frequency range: 7–14%)25,26 and LVEF
recovery to ≥35% (frequency range: 43–74%)22,26 following CRT.
There are several issues to consider in the interpretation and gen-
eralization of these data. First, there was a significant variation in the
timing of LVEF reassessment (range: 4–20 months). In studies in
which LVEF reassessment was relatively early, we cannot rule out
the possibility of subsequent LVEF improvement in patients categor-
ized as LVEF non-responders or the impact of continued LV reverse
remodelling in LVEF responders.27 Secondly, the inclusion of studies
which discounted ICD therapy between implant and LVEF reassess-
ment importantly allowed for the consideration of a non-linear dis-
tribution of SCD risk following CRT. Given the relationship
between lower LVEF and increased VTA risk, inclusion of studies
that did not perform blanking would only bias the IRD towards
the null to the extent that ICD therapies are occurring early post-
implant in eventual CRT responders. Thirdly, the majority of
patients across studies had a primary prevention indication for
ICD implant and overall rates of ICD therapy are likely to be higher
in a secondary prevention population. In the three studies
which allowed for stratification by ICD indication,4,6,9 regardless
of LVEF recovery definition (≥35 or ≥45%), patients with a primary
prevention indication were at very low risk of ICD therapy
post-CRT (0.4–0.8/100 person-years). Fourthly, device program-
ming was only reported in two studies5,6 and we cannot rule out
heterogeneity introduced by the lack of standardization in ICD pro-
gramming or provide sub-analysis regarding the incidence of VTA
not meeting criteria for ICD therapy or those terminated with
ATP alone. In addition, the magnitude of ICD therapy rates was like-
ly higher than contemporary practice considering that all studies
were performed prior to the recent demonstration of the salutary
effects of more liberal ICD programming.28 Finally, given the ab-
sence of individual patient data available in this meta-analytic
synthesis, we are unable to adjust for possible confounders which
may have been independently related to both LV reverse remodel-
ling (improved LVEF) and VTA risk. For example, in the
MADIT-CRT substudy included in this meta-analysis,5 LBBB and
gender were associated with both LVEF normalization and reduced
VTA risk, although importantly the relationship between LVEF re-
covery and reduced VTA remained significant even with adjustment
for these and other covariates associated with LVEF recovery.
Role of implantable
cardioverter-defibrillatorin cardiac
resynchronization therapy: balancing
efficacy, cost-effectiveness, and morbidity
In patients undergoing CRT, there remains no consensus recom-
mendation regarding the role of continued ICD therapy in patients
with evidence of LVEF recovery. Beyond questions of efficacy, add-
itional implications of continued ICD therapy in patients undergoing
CRT include short- and long-term ICD device complications,29,30
cost-effectiveness of CRT-D vs. CRT-P therapy,31 and the morbidity
and clinical implications of inappropriate ICD therapy.32 The ever-
increasing incidence of HF and patients eligible for CRT,1 coupled
with the contemporary predominance of CRT-D implantation
amongst CRT implants (e.g. 80% in the United States, .75% global-
ly),2,33 suggests that the population of patients for whom this
decision-making will be impactful will only increase with time.
The efficacy of ICD therapy reflects the integration of the abso-
lute and relative prevalence of SCD as well as the temporal distribu-
tion of SCD risk. Given the time-dependent influence of CRT on LV
reverse remodelling and heart failure status, CRT may modify all
three of these parameters. With respect to absolute risk, these
data support a significant absolute reduction in VTA to clinically sig-
nificant low rates with LVEF recovery post-CRT (2.3 and 5.6/100
person-years for LVEF recovery of ≥45 and ≥35%). The absolute
SCD risk is likely even lower than the rates identified given that
only a fraction of appropriate ICD therapies would have aborted
sudden death.34 The efficacy of ICD therapy in CRT patients with
LVEF recovery must additionally integrate competing mechanisms
of death. Age, NYHA class, as well as non-cardiac comorbidities
have each been shown to impact the distribution of modes of death
and by extension ICD efficacy in patients with systolic failure.35 In
the largest, real-world cohort assessing mode of death following
CRT-D36 annual mortality was3% (annualized over 8-year follow-
up) which was similar to randomized controlled trials of CRT with
mild HF (e.g. MADIT-CRT)37 but lower than trials of more advanced
HF (COMPANION, CARE-HF; annual mortality 9–12%).17,19 In this
real-world CRT cohort, the most common mode of death was HF
mortality (43% of all deaths; 3%/year) followed by non-cardiac death
(31% of all deaths; 2.3%/year). The incidence of sudden death was
very low (7% of all deaths; 0.5%/year) which may be attributable
both to difficulties in adjudication in real-world cohorts as well as
the possibility that effective ICD therapy shifted the mode of death
(e.g. from SCD to HF-related).
Decision-making regarding ICD therapy in CRT must also reflect
cost-effectiveness considerations as well as the risks associated with
ICD implantation. As shown previously in the CARE-HF cohort,31
when compared with medical therapy, the incremental cost of
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CRT-D per life year gained is significantly higher than that of CRT-P
(e.g. for 65-year-old patient: E35 864 vs. E7011). The cost-
effectiveness discrepancy in patients with LVEF recovery may be
even higher given that the efficacy of ICD therapy in this population
is likely lower than that identified in CARE-HF. Additional risk-
benefit considerations must also account for the incidence of ICD
lead failure/malfunction (15% over 3 years),30 complications asso-
ciated with device replacement,29 and the morbidity associated
with inappropriate ICD therapy including worsened quality-of-life
and clinical outcome.32 Only a minority of studies5,9 included in
this meta-analysis provided discrete data regarding inappropriate
ICD therapies or device-related morbidity which would only under-
estimate the risks associated with ICD therapy in patients with LVEF
recovery.
Clinical implications
While the definition of clinically meaningful survival benefit with
ICD therapy remains controversial,34 previous investigators have
used a number needed to treat (NNT) threshold of 50.38 As shown
recently, assuming a relative risk reduction in SCD of 40% with
ICD therapy (qualitatively similar to SCD risk reduction of CRT-D
vs. OMT in COMPANION),18 the baseline risk of SCD would need
to exceed 3% per year to reach the NNT threshold of 50.38 By this
admittedly crude approach, and taking the extreme that 100% of ap-
propriate ICD therapy was associated with aborted SCD, patients
with LVEF recovery to ≥45% and those with a primary prevention
ICD indication and LVEF recovery (≥35 or ≥45%) in this
meta-analysis would not warrant replacement of ICD at the time
of generator replacement. Indeed, recent appropriate-use guide-
lines, acknowledging the lack of supportive data, suggest deferral
of continued ICD therapy may be appropriate in patients with CRT
implanted for primary prevention with evidence for LVEF recovery
(.35%) and no appropriate ICD therapy during the initial implant
duration.39 Counterbalancing this perspective are the recent
contemporary demonstrations of worsened survival associated
with CRT-P compared with CRT-D even with guideline-directed
implantation of CRT-P in ‘low VTA risk’ patients (female, non-
ischaemic, and no prior VTA).40,41 Ultimately, given the hetero-
geneity and dearth of data highlighted in this meta-analysis, a
randomized controlled assessment of deferred ICD therapy in
post-CRT patients at low absolute risk for VTA may be warranted.
Study limitations
There are several limitations inherent to this analysis, many of which
have already been reviewed. Additionally, given the granularity of
the data we were unable to assess the impact of NYHA improve-
ment which has been established as a risk factor for appropriate
ICD therapy and possible modifier of ICD efficacy.34 Secondly,
there was incomplete reporting and significant variation in anti-
arrhythmic drug use across studies and we are unable to rule out
confounding related to this. Thirdly, given the established discrep-
ancy between treated VTA and aborted sudden death, the absolute
rates SCD are likely lower for all subgroups assessed.34 Fourthly, al-
though the majority of patients examined underwent ICD for pri-
mary prevention indication, lack of subgroup analysis limited more
robust stratification by ICD indication. Finally, the duration of
follow-up across studies was relatively short and longer assessment
for ICD therapies are likely warranted to justify change in clinical
practice.
Conclusion
Recovery of LVEF post-CRT is associated with significantly reduced
appropriate ICD therapy. Patients with recovery of LVEF to ≥45%
and those with a primary prevention indication for ICD with LVEF
recovery appear to be at lowest risk. A prospective randomized
evaluation of the need for continued ICD therapy in patients with
LVEF recovery, utilizing standardized ICD programming, may be
warranted.
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X-ray-free implantation of a permanent pacemaker during pregnancy
using a 3D electro-anatomic mapping system
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A 30-year-old patient presented with new-onset
dizziness and palpitations in her 9th week of ges-
tation. Physical examination revealed cannon
waves upon inspection of her jugular veins. Elec-
trolytes were within normal range. A 12-lead
electrocardiogram (ECG) showed sinus rhythm
at a rate of 94 bpm and complete atrio-
ventricular (AV) block with a junctional escape
rhythm at a rate of 60 bpm. No previous ECG
was available. In-hospital rhythm monitoring
showed repetitive episodes of junctional arrests
associated with dizziness. Whereas congenital
AV block could not be ruled out, the history sug-
gested a recent onset of the condition. The cause
of AV block remained unclear.
Because of the junctional escape rhythm with
intermittent arrests and the symptoms, implant-
ation of a permanent pacemaker was recom-
mended. Due to the early stage pregnancy, a
fluoroscopy-free approach was desired. For this
purpose, a 3D reconstruction of the vena cava,
the right atrium, and the right ventricle was per-
formed using an electroanatomic mapping system
(CARTO3) and a mapping catheter. A custom-
made cable consisting of crocodile clamps was
connected to a VDD pacemaker lead and a handle with 2 mm shielded pins was connected to the electroanatomic mapping system.
By defining the pacemaker lead as a diagnostic electrophysiologic catheter to be displayed in the mapping system, stable real-time visu-
alization of the pacemaker lead tip (in blue) in 3D from the innominate vein all the way into the apex of the right ventricle was feasible.
Connecting a pacemaker lead to an electroanatomic mapping system is feasible and enables X-ray-free implantation of a permanent
pacemaker.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2015. For permissions please email: journals.permissions@oup.com.
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